Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates

Advanced Drug Delivery Reviews

Volumn 59, Issue 7, 2007, Pages 617-630

  Blagden, N ^a   de Matas, M ^a   Gavan, P T ^a   York, P ^a  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

Author keywords

Co crystals; Crystal engineering; Crystallisation; Dissolution rate; Polymorphism; Solubility; Supramolecular chemistry

Indexed keywords

DISSOLUTION RATES; METASTABLE POLYMORPHS; PARTICLE MORPHOLOGY;

CRYSTAL ENGINEERING; CRYSTALLIZATION; DISSOLUTION; DRUG DELIVERY; POLYMORPHISM; SOLUBILITY; SUPRAMOLECULAR CHEMISTRY;

DRUG PRODUCTS;

ER 34122; GLIBENCLAMIDE; GRISEOFULVIN; LIPOXYGENASE INHIBITOR; PROSTAGLANDIN SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; BIOENGINEERING; CRYSTAL; CRYSTAL STRUCTURE; CRYSTALLIZATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW;

BIOLOGICAL AVAILABILITY; CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; DRUG DESIGN; PHARMACEUTICAL PREPARATIONS; SOLUBILITY; SOLVENTS;

EID: 34548023425     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2007.05.011     Document Type: Review

References (117)

1. Chaumeil J.C. Micronisation: a method of improving the bioavailability of poorly soluble drugs. Methods Find. Exp. Clin. Pharmacol. 20 3 (1998) 211-215
2. Agharkar S., Lindenbaum S., and Higuchi T. Enhancement of solubility of drug salts by hydrophilic counter-ions: properties of organic salts of an anti-malarial drug. J. Pharm. Sci. 65 5 (1976) 747-749
3. Amin K., Dannenfelser R.-M., Zielinski J., and Wang B. Lyophilization of polyethylene glycol mixtures. J. Pharm. Sci. 93 9 (2004) 2244-2249
4. Torchillin V.P. Micellar nanocarriers: pharmaceutical perspectives. Pharm. Res. 24 1 (2007) 1-16
5. Rajewski R.A., and Stella V.J. Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. J. Pharm. Sci. 85 11 (1996) 1142-1169
6. Humberstone A.J., and Charman W.N. Lipid-based vehicles for the oral delivery of poorly soluble drugs. Adv. Drug Deliv. Rev. 25 1 (1997) 103-128
7. Müller R.H., Jacobs C., and Kayser O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv. Drug Deliv. Rev. 47 1 (2001) 3-19
8. Subramanian S., and Zaworotko M.J. Manifestations of noncovalent bonding in the solid-state. 6. H-4(cyclam) (4+) (cyclam = 1,4,8,11-tetraazacyclotetra-decane) as a template for crystal engineering of network hydrogen-bonded solids. Can. J. Chem. 73 (1995) 414-424
9. Lehn J.M. Supramolecular chemistry - scope and perspectives molecules, supermolecules, and molecular devices. Angew. Chem., Int. Ed. Engl. 27 (1988) 89-112
10. von Hippel A.R. Molecular designing of materials. Science 138 (1962) 91
11. Schmidt G.M.J. Topochemistry. Part III. The crystal chemistry of some trans-cinnamic acids. J. Chem. Soc. (1964) 2014
12. Steed J.W., and Atwood J.L. Supramolecular Chemistry (2000), John Wiley & Sons, Ltd.
13. Desiraju G.R. Supramolecular synthons in crystal engineering - a new organic-synthesis. Angew. Chem., Int. Ed. Engl. 34 (1995) 2311-2327
14. Allen F.H. The Cambridge structural database: a quarter of a million crystal structures and rising. Acta Cryst., B 58 (2002) 380-388
15. Bruno I.J., Cole J.C., Edgington P.R., Kessler M.K., Macrae C.F., McCabe P., Pearson J., and Taylor R. New software for searching the Cambridge structural database and visualising crystal structures. Acta Cryst., B 58 (2002) 389-397
16. Huang C.M., Leiserow L., and Schmidt G.M.J. Molecular packing modes. 11. Crystal-structures of 2-1 complexes of benzamide with succinic acid and furamide with oxalic-acid. J. Chem. Soc., Perkin Trans. 2 (1973) 503-508
17. Etter M.C. Aggregate structures of carboxylic-acids and amides. Isr. J. Chem. 25 (1985) 312-319
18. Etter M.C. Encoding and decoding hydrogen bond patterns of organic compounds. Acc. Chem. Res. 23 (1990) 120-126
19. Caira M.R., Nassimbeni L.R., and Wildervanck A.F. Selective formation of hydrogen-bonded cocrystals between a sulfonamide and aromatic carboxylic-acids in the solid-state. J. Chem. Soc., Perkin Trans. 2 (1995) 2213-2216
20. Aakeröy C.B., Beatty A.M., and Zou M. Building organic assemblies with 2-pyridone and dicarboxylic acids: relating molecular conformation and synthon stability to crystal structure. Mater. Res. Bull. (1998) 225-241
21. Carrow C.J., and Wheeler K.A. Structural studies of trimeric pyridinium carboxylate carboxylic acid cocrystals. Mater. Res. Bull. (1998) 263-275
22. Pedireddi V.R., Chatterjee S., Ranganathan A., and Rao C.N.R. A study of supramolecular hydrogen bonded complexes formed by aliphatic dicarboxylic acids with azaaromatic donors. Tetrahedron 54 (1998) 9457-9474
23. Aakeröy C.B., Beatty A.M., Nieuwenhuyzen M., and Zou M. Organic assemblies of 2-pyridones with dicarboxylic acids. Tetrahedron 56 (2000) 6693-6699
24. Batchelor E., Klinowski J., and Jones W. Crystal engineering using co-crystallisation of phenazine with dicarboxylic acids. J. Mater. Chem. 10 (2000) 839-848
25. Edwards M.R., Jones W., and Motherwell W.D.S. Influence of dicarboxylic acid structure on tape networks in co-crystals of 2-pyridone. Cryst. Eng. 5 (2002) 25-36
26. Pedireddi V.R., and PrakashaReddy J. Unique homo and hetero carboxylic acid dimer-mediated supramolecular assembly: rational analysis of crystal structure of 3,5-dinitrobenzoic acid and 4-(N-methylamino)benzoic acid. Tetrahedron Lett. 43 (2002) 4927-4930
27. Shan N., Batchelor E., and Jones W. Co-crystal structures of 4,7-phenanthroline and carboxylic acids: synthon competition and prediction. Tetrahedron Lett. 43 (2002) 8721-8725
28. Shan N., Bond A.D., and Jones W. Crystal engineering using 4,4-apos;-bipyridyl with di- and tricarboxylic acids. Cryst. Eng. 5 (2002) 9-24
29. Shan N., Bond A.D., and Jones W. Supramolecular synthons in the co-crystal structures of 2-aminopyrimidine with diols and carboxylic acids. Tetrahedron Lett. 43 (2002) 3101-3104
30. Zhang J., Wu L., and Fan Y. Heterosynthons in molecular complexes of azopyridine and 1,2-bis(4-pyridyl)ethylene with dicarboxylic acids. J. Mol. Struct. 660 (2003) 119-129
31. Cabrerra N., and Vermilea D.A. Growth Perfection of Crystals vol. 393 (1958), Chapman and Hall, London
32. Burton W.K., Cabrera N., and Frank F.C. The growth of crystals. Philos. Trans. R. Soc. 243 (1951) 299-358
33. Human H.J., van der Eerden J.P., Jetten L.A.M.J., and Oderkerken J.G.M. On the surface roughening transition of faceted to non faceted growth of diphenyl for different organic solvents and the melt. J. Cryst. Growth 51 (1981) 598-600
34. Addadi L., Berkovitch-Yellin Z., Weissbuch I., Lahav M., and Leiserwitz L. A link between macroscopic phenomena and molecular chirality crystals as probes for the direct assignment of absolute configuration for chiral molecules. Top. Stereochem. 16 (1986) 2-83
35. Heng J.Y.Y., Thielmann F., and Williams D.R. The effects of milling on the surface properties of form I paracetamol crystals. Pharm. Res. 23 8 (2006) 1918-1927
36. Adhiyaman R., and Basu S.K. Crystal modification of dipyridamole using different solvents and crystallisation conditions. Int. J. Pharm. 321 1-2 (2006) 27-34
37. Nokhodchi A., Bolourtchian N., and Dinarvand R. Crystal modification of phenytoin using different solvents and crystallisation conditions. Int. J. Pharm. 250 1 (2003) 85-97
38. Chow A.H.L., Hsia C.K., Gordon J.D., Young J.W.M., and Vargha-Butler E.I. Assessment of wettability and its relationship to the intrinsic dissolution rate of doped phenytoin crystals. Int. J. Pharm. 126 1,2 (1995) 21-28
39. Hörter D., and Dressman J.B. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv. Drug Deliv. Rev. 46 (2001) 75-87
40. Buckton G., Choularton A., Beezer A.E., and Chatham S.M. The effect of comminution technique on the surface energy of a powder. Int. J. Pharm. 47 1-3 (1988) 121-128
41. Ward G.H., and Schultz R.K. Process induced crystallinity changes in albuterol sulfate and its effect on powder physical stability. Pharm. Res. 12 5 (1995) 773-779
42. Hu J., Johnston K.P., and Williams III R.O. Nanoparticle engineering processes for enhancing the dissolution rates of poorly water soluble drugs. Drug Dev. Ind. Pharm. 30 3 (2004) 233-245
43. Maheshwari M., Jahagirdar H., and Paradkar A. Melt sonocrystallisation of ibuprofen: effect on crystal properties. Eur. J. Pharm. Sci. 25 1 (2005) 41-48
44. Paradkar A., Maheshwari M., Kamble R., Grimsey I., and York P. Design and evaluation of celecoxib porous particles using melt sonocrystallisation. Pharm. Res. 23 6 (2006) 1395-1400
45. M.H. Hanna, P. York, Method and apparatus for the formation of particles, U.S. Patent 5,851,453 (1998).
46. York P. Strategies for particle design using supercritical fluid technologies. PSTT 2 (1999) 430-440
47. Türk M., Helfgen B., Hils P., Lietzow R., and Schaber K. Micronisation of pharmaceutical substances by rapid expansion of supercritical fluid solutions (RESS): experiments and modeling. Part. Part. Syst. Charact. 19 (2002) 327-335
48. Türk M., Hils P., Helfgen B., Schaber K., Martin H.-J., and Wahl M.A. Micronisation of pharmaceutical substances by the rapid expansion of supercritical solutions (RESS): a promising method to improve bioavailability of poorly soluble pharmaceutical agents. J. Supercrit. Fluids 22 (2002) 75-84
49. Eckert C.A., Knutson B.L., and Debenedetti P.G. Supercritical fluids as solvents for chemical and materials processing. Nature 383 (1996) 313-318
50. Tom J.W., and Debenedetti P.G. Particle formation with supercritical fluids - a review. J. Aerosol Sci. 22 (1991) 555-584
51. Gerard D., and Quirin K.W. Dense Gases Extraction and Refining (1986), Springer-Verelag, Berlin 226-227
52. S.G. Frank, C. Ye, Small particle formation and dissolution rate enhancement of relatively insoluble drugs using rapid expansion of supercritical solutions (RESS) processing, Proceedings of the Fifth International Symposium on Supercritical Fluids.
53. Foster N.R., Dehghani F., Charoenchaitrakool M., and Warwick B. Application of dense gas techniques for the production of fine particles. AAPS PharmSci 5 (2003) 105-111
54. Perrut M., Jung J., and Leboeuf F. Enhancement of dissolution rate of poorly-soluble active ingredients by supercritical fluid processes, Part I: micronisation of neat particles. Int. J. Pharm. 288 (2005) 3-10
55. Warwick B., Dehghani F., Foster N.R., Biffin J.R., and Regtop H.L. Micronisation of copper-indomethacin using gas anti-solvent processes. Ind. Eng. Chem. Res. 41 (2002) 1993-2004
56. Weidner E., Knez Z., and Novak Z. PGSS-a new process for powder generation. Proceedings of the third international symposium on supercritica; fluids. Tome 3 (1994) 229-234
57. Knez Z. Micronisation of pharmaceuticals using supercritical fluids, proceedings of the seventh meeting on supercritical fluids. Tome 1 (2000) 1-26
58. Singhal D., and Curatolo W. Drug polymorphism and dosage form design: a practical perspective. Adv. Drug Deliv. Rev. 56 (2004) 335-347
59. Aguiar A.J., KRC Jr. J., Kinkel A.W., and Samyn J.C. Effect of polymorphism on the absorption of chloramphenicol from chloramphenicol palmitate. J. Pharm. Sci. 56 7 (1967) 847-853
60. Ostwald W.Z. Studies on formation and transformation of solid materials. Phys. Chem. 22 (1897) 289-330
61. Cardew P.T., and Davey R.J. Kinetic of Solvent Mediated Polymoprhic Transformations. Proocedings of the Royal Society vol. 398 (1985) 415-428
62. Gavezzotti A. Ten years of experience in polymorph prediction: what next?. Cryst. Eng. Commun. 18 (2002) 343-347
63. Dunitz J. Crystal and co-crystal: a second opinion. Chem. Commun. 5 (2003) 545-548
64. Davey R.J., Allen K., Blagden N., Cross W.I., Lieberman H.F., Quayle M.J., Righni S., Seton L., and Tiddy G.J.T. Cryst. Eng. Commun. 4 47 (2002) 257-264
65. Bernstein J. Polymorphism in Molecular Crystals (2002), Oxford University Press
66. Perlstein J. Molecular self assemblies: 4. Using Kitaigorodskii's Aufbau principle for quantitatively predicting the packing geometry of semiflexible organic molecules in translation monolayer aggregates. J. Am. Chem. Soc. 116 (1994) 11420-11432
67. Day G.M., Motherwell W.D.S., Ammon H.L., Boerrigter S.X.M., Della Valle R.G., Venuti E., Dzyabchenko A., Dunitz J.D., Schweizer B., van Eijck B.P., Erk P., Facelli J.C., Bazterra V.E., Ferraro M.B., Hofmann D.W.M., Leusen F.J.J., Liang C., Pantelides C.C., Karamertzanis P.G., Price S.L., Lewis T.C., Nowell H., Torrisi A., Scheraga H.A., Arnautova Y.A., Schmidt M.U., and Verwer P. A third blind test of crystal structure prediction. Acta Cryst., B 61 5 (2005) 511-527
68. Blagden N., and Davey R.J. Polymorph selection: challenges for the future. Cryst. Growth Des. 3 6 (2003) 873-885
69. Gavezzotti A. Molecular aggregation of acetic acid in a carbon tetrachloride solution: a molecular dynamics study with a view to crystal nucleation. Chem. Eur. J. 5 (1999) 567
70. Price S.L. The computational prediction of pharmaceutical crystal structures and polymorphism. Adv. Drug Deliv. Rev. 56 (2004) 301-319
71. Κato Y., Okamoto Y., Nagasawa S., and Ishihara I. Relationship between polymorphism and bioavailability of drug. IV. New polymorphic forms of phenobarbital. Chem. Pharm. Bull. 32 10 (1984) 4170-4174
72. Salole E.G., and Al-Sarraj F.A. Spiranolactone crystal forms. Drug Dev. Ind. Pharm. 11 4 (1985) 855-864
73. Kobayashi Y., Ito S., Itai S., and Yamamoto K. Physicochemical properties and bioavailability of carbamazepine polymorphs and dihydrate. Int. J. Pharm. 193 (2000) 137-146
74. Pandit J.K., Gupta S.K., Gode K.D., and Mishra B. Effect of crystal form on the oral absorption of phenylbutazone. Int. J. Pharm. 21 (1984) 129-132
75. Tian F., Sandler N., Aaltonen J., Lang C., Saville D.J., Gordon K.C., Strachan C.J., Rantanen J., and Rades T. Influence of polymorphic form, morphology, and excipient interactions on the dissolution of carbamazepine compacts. J. Pharm. Sci. 96 3 (2007) 584-594
76. Kushida I., Ichikawa M., and Asakawa N. Improvement of dissolution and oral absorption of ER-3421, a poorly water-soluble dual 5-lipoxygenase/cyclooxygenase inhibitor with anti-inflammatory activity by preparing solid dispersion. J. Pharm. Sci. 91 1 (2002) 258-266
77. Yu L. Amorphous pharmaceutical solids: preparation, characterization and stabilization. Adv. Drug Deliv. Rev. 48 (2001) 27-42
78. Chiou W.L., and Riegelman S. Pharmaceutical applications of solid dispersion systems. J. Pharm. Sci. 60 (1971) 1281-1302
79. Sekiguchi K., and Obi A.T.M. Chem. Pharm. Bull. 9 (1961) 866-872
80. Emara L.H., Badr R.M., and Elbary A.A. Improving the dissolution and bioavailability of nifedipine using solid dispersions and solubilizers. Drug Dev. Ind. Pharm. 28 7 (2002) 795-807
81. Kai T., Akiyama Y., Nomura S., and Sato M. Oral absorption improvement of poorly soluble drug using solid dispersion technique. Chem. Pharm. Bull. 44 3 (1996) 568-571
82. Juppo A.M., Boissier C., and Khoo C. Evaluation of solid dispersion particles prepared by SEDS. Int. J. Pharm. 250 2 (2003) 385-401
83. Forster A., Hempenstall J., and Rades T. Characterization of glass solutions of poorly water-soluble drugs produced by melt extrusion with hydrophilic amorphous polymers. J. Pharm. Pharmacol. 53 3 (2001) 303-315
84. Tashtoush B.M., Al-Qahi Z.S., and Najib N.M. In vitro and in vivo evaluation of glibenclamide in solid dispersion systems. Drug Dev. Ind. Pharm. 30 6 (2004) 601-607
85. Law D., Schmitt E.A., Marsh K.C., Everitt E.A., Wang W., Fort J.J., Krill S.L., and Qiu Y. Ritonovir-PEG8000 amorphous solid dispersions: in vitro and in vivo evaluations. J. Pharm. Sci. 93 3 (2004) 563-570
86. Aakeröy C.B., Beatty A.M., Helfrich B.A., and Nieuwenhuyzen M. Do polymorphic compounds make good cocrystallising agents? A structural case study that demonstrates the importance of synthon flexibility. Cryst. Growth Des. 3 (2003) 159-165
87. Otto S., and Sanders J.M. Supramolecular libraries. In: Atwood J.L., and Steed J.W. (Eds). Encylopedia of Supramolecular Chemistry vol. 2 (2004), CRC, Taylor Francis 1427-1433
88. Burrows A. Concepts in crystal engineering. In: Atwood J.L., and Steed J.W. (Eds). Encylopedia of Supramolecular Chemistry vol. 1 (2004), CRC, Taylor Francis 319-325
89. Aakeröy C.B. Crystal engineering: strategies and architectures. Acta Cryst., B 53 (1997) 569-586
90. Desiraju G.R. Crystal and co-crystal. Cryst. Eng. Commun. 5 (2003) 466-467
91. Dunitz J.D. Crystal and co-crystal: a second opinion. Cryst. Eng. Commun. 5 (2003) 506
92. Ito K., and Sekiguchi K. Studies on the molecular compounds of organic medicinals. Application of the solubility product principle and consideration by the phase rule to the solubility phenomena of the molecular compound of sulphanilamide and sulfathiazole. Chem. Pharm. Bull. 14 3 (1996) 255-262
93. Morissette S.L., Almarsson O., Peterson M.L., Remenar J.F., Read M.J., Lemmo A.V., Ellis S., Cima M.J., and Gardner C.R. High-throughput crystallisation: polymorphs, salts, co-crystals and solvates of pharmaceutical solids. Adv. Drug Deliv. Rev. 56 (2004) 275-300
94. Almarsson Ö., and Zaworotko M.J. Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines?. Chem. Commun. (2004) 1889-1896
95. Trask A.V., Motherwell W.D.S., and Jones W. Solvent-drop grinding: green polymorph control of co-crystallisation. Chem. Comm. (2004) 890-891
96. Rodriguez-Spong B., Price C.P., Jayasankar A., Matzger A.J., and Rodriguez-Hornedo N. General principles of pharmaceutical solid polymorphism: a supramolecular perspective. Adv. Drug Deliv. Rev. 56 (2004) 241-274
97. Taylor L.S., and Zografi G. Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions. Pharm. Res. 14 (1997) 1691-1698
98. Tong P., and Zografi G. A study of amorphous molecular dispersions of indomethacin and its sodium salt. J. Pharm. Sci. 90 (2001) 1991-2004
99. Remenar J.F., Morisette S.L., Peterson M.L., Moulton B., MacPhee M.J., Guzman H.R., and Almarsson O. Crystal engineering of novel co-crystals of a triazole drug with 1,4-dicarboxylic acids. J. Am. Chem. Soc. 125 (2003) 8456-8457
100. Oswald I.D.H., Allan D.R., McGregor P.A., Motherwell W.D.S., Parsons S., and Pulham C.R. The formation of paracetamol (acetaminophen) adducts with hydrogen-bond acceptors. Acta Cryst., B 58 (2002) 1057-1066
101. Serajuddin A.T.M., and Pudipeddi M. In: Stahl P.H., and Wermuth C.G. (Eds). Handbook of Pharmaceutical Salts (2002), Zûrich and Wiley-VCH, Weinheim 138
102. Trask A.V., Motherwell W.D.S., and Jones W. Pharmaceutical cocrystallisation: engineering a remedy for caffeine hydration. Cryst. Growth Des. 5 (2005) 1013-1021
103. Zaworotko M. Polymorphism in co-crystals and pharmacuetical co-crystals. XX Congress of the International Union of Crystallography, Florence (2005)
104. Portalone G., and Colapietro M. First example of cocrystals of polymorphic maleic hydrazide. J. Chem. Crystallogr. 34 (2004) 609-612
105. Fleischman S.G., Kuduva S.S., McMahon J.A., Moulton B., Walsh R.D.B., Rodriguez-Hornedo N., and Zaworotko M.J. Crystal engineering of the composition of pharmaceutical phases: multiple-component crystalline solids involving carbamazepine. Cryst. Growth Des. 3 (2003) 909-919
106. Etter M.C., Reutzel S.M., and Choo C.G. Self-organization of adenine and thymine in the solid-state. J. Am. Chem. Soc. 115 (1993) 4411-4412
107. Lynch D.E., Smith G., Byriel K.A., and Kennard C.H.L. Molecular cocrystals of carboxylic-acids. 1. The crystal-structures of the adducts of indole-3-acetic-acid with pyridin-2(1h)-one, 3,5-dinitrobenzoic acid and 1,3,5-trinitrobenzene Australian. J. Chem. 44 6 (1991) 809-819
108. Pedireddi V.R., Jones W., Chorlton A.P., and Docherty R. Creation of crystalline supramolecular arrays: a comparison of co-crystal formation from solution and by solid state grinding. Chem. Commun. (1996) 987-988
109. Ling A.R., and Baker J.L. J. Chem. Soc. 63 (1893) 1314-1327
110. Shan N., Toda F., and Jones W. Mechanochemistry and co-crystal formation: effect of solvent on reaction kinetics. Chem. Commun. 20 (2002) 2372-2373
111. Sangster J. Phase diagrams and thermodynamic properties of binary and ternary systems based on nitro aromatic compounds. J. Phys. Chem. Ref. Data 26 2 (1997) 351-502
112. Sangster J. Phase diagrams and thermodynamic properties of binary systems of drugs. J. Phys. Chem. Ref. Data 28 4 (1999) 889-930
113. Nehm S.J., Rodriguez-Spong B., and Rodriguez-Hornedo N. Phase solubility diagrams of cocrystals are explained by solubility product and solution complexation. Cryst. Growth Des. 6 2 (2006) 592-600
114. McNamara D.P., Childs S.L., Giordano J., Iarriccio A., Cassidy J., Shet M.S., Mannion R., O'Donnell E., and Park A. Use of glutaric acid cocrystal to improve oral bioavailability of a low solubility API. Pharm. Res. 23 8 (2006) 1888-1897
115. Walsh R.D.B., Bradner M.W., Fleischman S., Morales L.A., Moulton B., Rodriguez-Hornedo N., and Zaworotko M.J. Crystal engineering of the composition of pharmaceutical phases. Chem. Commun. 2 (2003) 186-187
116. Byrn S.R., Pfeiffer R.R., and Stowell J.G. Solid-State Chemistry of Drugs Solid-State Chemistry of Drugs. 2nd Edition (1999), SSCI, Inc., West Lafayette, Indiana
117. Kwei G.Y., Novak L.B., Hettrick L.A., Reiss E.R., Ostovic D., Loper A.E., Lui C.Y., Higgins R.J., Chen I.W., and Lin J.H. Regiospecific intestinal-absorption of the HIV protease inhibitor L-735,524 in Beagle dogs. Pharm. Res. 12 (1995) 884-888